At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-centre Phase II, Double-Blind, Randomised Study of Savolitinib in Combination With Osimertinib vs Savolitinib in Combination With Placebo in Patients With EGFRm+ and MET Amplified Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib
In Brief
A Phase 2 clinical trial evaluating Osimertinib + Savolitinib and Savolitinib + Placebo for Non-Small Cell Lung Cancer. Active but no longer recruiting, targeting 30 participants across 21 sites in 6 countries.
Detailed Summary
This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with osimertinib.
Study Details
Timeline
Interventions
Osimertinib 80 mg oral QD Savolitinib 300mg oral QD
Savolitinib 300mg Oral QD Placebo to Osimertinib 80mg oral QD